Like most CROs, Parexel International relies on Big Pharma for most of its service revenue. But the recent explosion in biotech IPOs and venture capital deals has put a lot of money in the hands of small drugmakers, and that's changing the approach for the industry's largest contractors, a company exec said.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
POPULAR COMMENT THREADS
German contract researcher Evotec has signed a deal with Medicines for Malaria Venture, lending its expertise to the nonprofit's efforts to encourage neglected disease R&D around the world.
AstraZeneca is looking to bring more of its IT work in-house, spending money to stand up an Indian hub that will replace much of its contract spend in the field.
U.K. drug development outfit Ergomed has come out the other end of its London IPO, touting a range of R&D partnerships that give it a chance to share the rewards of its clients' work.
The recently IPO'd Catalent has signed a deal with biotech Cingulate Therapeutics to help develop a duo of candidates for ADHD, tapping its expertise in crafting controlled-release tablets.
Germany's Evotec has joined a trio of research projects focused on multiple sclerosis, contributing its developmental know-how to some early-stage R&D.
Indian CRO GVK Biosciences is working to get back in the good graces of European regulators after inspectors found evidence that its employees doctored clinical trial results.
From Our Sister Sites
Pharma's social media evangelists have been urging companies to lend an ear to the chatter on Twitter, Facebook, patient forums, physician networking sites and the like. It's a way to engage with patients, monitor doctors' opinions, tailor marketing and spot safety concerns, they say.
When John Vansteenkiste of Belgium University Hospitals Leuven reported the full results of GlaxoSmithKline's MAGE-A3 failure at the European Society of Medical Oncology's annual congress last weekend, he wasn't the first to outline a cancer vaccine flop. But he did offer a way out from under the dark cloud hanging over the field, and it's one that some cancer vaccine makers are already embracing.